maritide glp-1 vs Tirzepatide: Similarities and Differences Trial Scorecard: MariTide

Description

June 10, 2026 Expert Hearing Set for September in GLP-1 GI Injury MDL The next major event in the GLP-1 gastrointestinal injury litigation is expected to be a Rule 702 expert hearing in September 2026

Plans that previously refused weight-loss-only coverage are increasingly covering Zepbound when prescribed for the OSA indication, because OSA is a covered disease state

Generally speaking, people can lose about 10 to 20 percent of their body weight in nine months, although this can vary according to the medication, according to some research

Eylea (aflibercept) Disease area(s): Ophthalmology Manufacturer(s): Regeneron/Bayer 2024 Sales (USD): $9.55 billion Why it sold so well: Eylea registered strong sales in 2024, driven by the introduction of Eylea HD, which received FDA approval in 2023 and is an 8 mg formulation offering extended dosing intervals for retinal diseases

Additionally, in the analyses of WL after surgery and before treatment, the intercepts were also positive for age with p-value = 0.07 and p-value = 0.09 for GLP-1RAs and placebo treatment groups, respectively, suggesting that older age may be associated with slightly reduced WL